as of 12-08-2025 4:00pm EST
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 725.5M | IPO Year: | 2020 |
| Target Price: | $30.00 | AVG Volume (30 days): | 7.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.86 - $29.51 | Next Earning Date: | 11-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Director
Avg Cost/Share
$8.33
Shares
13,086
Total Value
$108,975.52
Owned After
744,140
Director
Avg Cost/Share
$8.06
Shares
11,914
Total Value
$95,865.12
Owned After
744,140
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Harmon Cyrus | OLMA | Director | Sep 18, 2025 | Sell | $8.33 | 13,086 | $108,975.52 | 744,140 | |
| Harmon Cyrus | OLMA | Director | Sep 16, 2025 | Sell | $8.06 | 11,914 | $95,865.12 | 744,140 |
See how OLMA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "OLMA Olema Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.